Delving into the Latest Updates on Thallium (201Tl) Chloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

Thallous Chloride (201TlCl), 塩化タリウム, 塩化第一タリウム（201Tl）

+ [4]

Target

TGF-β

Action

inhibitors, enhancers

Mechanism

TGF-β inhibitors(Transforming growth factor beta inhibitors), SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

NeoplasmsNervous System DiseasesCardiovascular Diseases+ [4]

Active Indication

Coronary Artery DiseaseNeoplasmsCardiovascular Diseases+ [12]

Inactive Indication-

Originator Organization

Lantheus Medical Imaging, Inc.

Active Organization

Curium US Holdings LLC

Nihon Medi-Physics Co., Ltd.PDRadiopharma, Inc.

Inactive Organization

Lantheus Medical Imaging, Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (16 Dec 1977),

Cardiovascular DiseasesCoronary Artery DiseaseMyocardial Infarction+ [1]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaClTl

InChIKeyGBECUEIQVRDUKB-RYDPDVNUSA-M

CAS Registry55172-29-7

Breast cancer is a leading cause of death in women, and its management highly depends on early disease diagnosis and monitoring. This remains challenging due to breast cancer's heterogeneity and a scarcity of specific biomarkers that could predict responses to therapy and enable personalized treatment. This Perspective describes the diagnostic landscape for breast cancer management, molecular strategies targeting receptors overexpressed in tumors, the theranostic potential of the oxytocin receptor (OTR) as an emerging breast cancer target, and the development of OTR-specific optical and nuclear tracers to study, visualize, and treat tumors. A special focus is on the chemistry and pharmacology underpinning OTR tracer development, preclinical in vitro and in vivo studies, challenges, and future directions. The use of peptide-based tracers targeting upregulated receptors in cancer is a highly promising strategy complementing current diagnostics and therapies and providing new opportunities to improve cancer management and patient survival.

01 Oct 2023·Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Lung-to-heart ratio analysis using virtual planar images obtained from myocardial perfusion SPECT data: A phantom and clinical studies

Article

Author: Imoto, Akira ; Tateishi, Emi ; Ohta, Yasutoshi ; Murakawa, Keizo ; Fukuda, Tetsuya

BACKGROUNDS:

The lung-to-heart ratio (L/H ratio) in myocardial perfusion scintigraphy (MPS) is a useful marker that complements the sensitivity of ischemia detection. However, it requires planar imaging acquired following a separate protocol in addition to single-photon emission computed tomography (SPECT). We developed a novel method for constructing virtual planar image (VPI) from SPECT data.

METHODS:

Myocardial phantoms using Tl-201 were built with different amounts of radioactivity in the lungs. SPECT data and conventional planar images of these phantoms were collected with an Anger-type gamma camera. VPIs were constructed by adding all coronal images reconstructed from SPECT data. The clinical utility of VPIs obtained from 52 patients who underwent MPS with Tc-99m sestamibi was evaluated.

RESULTS:

The radioactivity linearity of VPIs was satisfactory, with a correlation coefficient of r ≥ .99 between the measured amounts of radioactivity and image counts. The L/H ratios obtained from VPI analysis were strongly correlated with those of conventional planar images with a correlation coefficient of r ≥ .99 in the phantom study and r = .929 in clinical application.

CONCLUSION:

The accuracy of VPI-based L/H ratio analysis was comparable to that of conventional planar image-based analysis. VPIs could be used as an alternative method of obtaining planar images in clinical settings.

01 Oct 2021·Nuclear medicine and molecular imaging

Simulating dose reduction for myocardial perfusion SPECT using a Poisson resampling method

Article

Author: Choi, So-Yeon ; An, Young-Sil ; Kim, Il-Hyun ; Lee, Su Jin ; Yoon, Joon-Kee

PURPOSE:

The purpose of this study was to determine the lowest Tl-201 dose that does not reduce the image quality of myocardial perfusion SPECT (MPS) by Poisson resampling simulation.

METHODS:

One hundred and twelve consecutive MPS data from patients with suspected or known coronary artery disease were collected retrospectively. Stress and rest MPS data were resampled using the Poisson method with 33%, 50%, 67%, and 100% count settings. Two nuclear medicine physicians assessed the image quality of reconstructed data visually by giving grades from - 2 to + 2. The summed stress score (SSS), summed rest score (SRS), and summed difference score (SDS) were obtained on the workstation. Image quality grades and semi-quantitative scores were then compared among these resampled images.

RESULTS:

The proportions of "adequate" image quality were 0.48, 0.75, 0.92, and 0.96 for the groups of images with 33%, 50%, 67%, and 100% data, respectively. The quality of the resampled images was significantly degraded at 50% and 33% count settings, while the image quality was not different between 67 and 100% count settings. We also found that high body mass index further decreased image quality at 33% count setting. Among the semi-quantitative parameters, SSS and SRS showed a tendency to increase with a decline in count.

CONCLUSION:

Based on the simulation results, Tl-201 dose for MPS can be reduced to 74 MBq without significant loss of image quality. However, the SSS and SRS can be changed significantly, and it needs to be further verified under the different conditions.

100 Deals associated with Thallium (201Tl) Chloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09GX01	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neoplasms	Japan	PDRadiopharma, Inc.	20 Dec 1991
Coronary Disease	United States	Curium US Holdings LLC	23 Oct 1979
Hyperparathyroidism	United States	Curium US Holdings LLC	23 Oct 1979
Bone Cancer	Japan	Nihon Medi-Physics Co., Ltd.	01 Aug 1978
Brain Cancer	Japan	Nihon Medi-Physics Co., Ltd.	01 Aug 1978
Heart Diseases	Japan	Nihon Medi-Physics Co., Ltd.	01 Aug 1978
Lung Cancer	Japan	Nihon Medi-Physics Co., Ltd.	01 Aug 1978
Mediastinal Cancer	Japan	Nihon Medi-Physics Co., Ltd.	01 Aug 1978
Parathyroid Diseases	Japan	Nihon Medi-Physics Co., Ltd.	01 Aug 1978
Soft Tissue Neoplasms	Japan	Nihon Medi-Physics Co., Ltd.	01 Aug 1978
Thyroid Cancer	Japan	Nihon Medi-Physics Co., Ltd.	01 Aug 1978
Cardiovascular Diseases	United States	Lantheus Medical Imaging, Inc.	16 Dec 1977
Coronary Artery Disease	United States	Lantheus Medical Imaging, Inc.	16 Dec 1977
Myocardial Infarction	United States	Lantheus Medical Imaging, Inc.	16 Dec 1977
Myocardial Ischemia	United States	Lantheus Medical Imaging, Inc.	16 Dec 1977

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2023	Not Applicable	Transthyretin Amyloid Cardiomyopathy	-	TL-201/TC-99M PYP (Tc-99m PYP)	jepbgntfci(wpyazpqxzp) = jnzczmhqrv mmbuepkrjw (uyklsuoakl )	-	28 Aug 2023
SNMMI2016	Not Applicable	Coronary Artery Disease	-	Tl-201 washout rate (Patients with 1-vessel disease)	ekrwnuttni(szorapnasn) = emjrwvgcat grgxvjsirr (ugpcspwxsf )	-	24 May 2016
SNMMI2016	Not Applicable	Coronary Artery Disease	-	Tl-201 washout rate (Patients with 2-vessel disease)	ekrwnuttni(szorapnasn) = lrkpwdabmz grgxvjsirr (ugpcspwxsf )	-	24 May 2016
EANM2010	Not Applicable	-	-	Tl-201 (Tc-99m-Tetrofosmin GSPECT)	hykfjhxpno(sexhjzjzct) = cebehsltvc jwomxctaen (lczixqubiv, +12.6)	-	10 Oct 2010